The U.S. Food and Drug Administration on Monday approved the first new drug for Alzheimer's disease, a controversial decision that came despite opposition from the agency's independent advisory committee and some Alzheimer's experts who said there was insufficient evidence that the drug could help patients.

From the NYT publication: The drug aducanumab, which will be marketed under the brand name Aduhelm, will be a monthly intravenous infusion designed to slow cognitive loss in people with mild memory and thinking problems.




